Bayer advances oncology pipeline with Vividion trial, shares trade firmer in DAX
23.06.2026 - 20:09:10 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 20:04.
Bayer (DE000BAY0017) highlights a further step in its oncology research as its subsidiary Vividion Therapeutics has begun dosing patients in a Phase Ib combination study of WRN inhibitor VVD-214 for advanced colorectal cancer, as disclosed in the company’s newsroom on June 23, 2026. The move comes while Bayer shares trade around the mid-30-euro range on Xetra as part of the DAX index, with prices recently quoted just below 39 euros according to German market data.
Vividion starts Phase Ib combo study
According to a June 23 update in Bayer’s newsroom, Vividion Therapeutics has treated the first patient in a global Phase Ib clinical study evaluating WRN inhibitor VVD-214 in combination therapy for patients with previously treated advanced colorectal cancer showing high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). The IR release of June 23, 2026 outlines the clinical trial design.
The study focuses on tumors with MSI-H or dMMR, genetic profiles that can make cancer cells particularly vulnerable to targeted approaches such as WRN inhibition. Vividion, which Bayer acquired to strengthen its access to chemoproteomics and novel drug targets, positions VVD-214 as part of an early-stage precision oncology portfolio aimed at difficult-to-treat solid tumors.
Oncology pipeline in the wider Bayer strategy
Bayer’s collaboration with Vividion fits into a broader strategy to replenish its pharmaceuticals pipeline, especially in oncology and cardiovascular diseases, following earlier pressures from patent expiries and litigation in other parts of the group. The company has repeatedly emphasized innovative small molecules and targeted therapies as a central growth pillar in investor presentations and recent earnings calls. MarketScreener’s company profile underscores this focus on specialty pharma.
Vividion contributes discovery capabilities that use chemoproteomics to identify previously undruggable targets, which Bayer management has described as a competitive edge in a crowded oncology market. The VVD-214 study adds another trial to a pipeline that already spans hematology, solid tumors and cell therapies, aiming to offset revenue concentration in established products over the coming years.
All news and analysis on the Bayer shares
Track current reports, analyst assessments and price data for Bayer alongside today’s update on the Vividion clinical program.
The product behind the stock
In pharmaceuticals, a representative example of Bayer’s innovative pipeline is the investigational WRN inhibitor VVD-214 from Vividion, designed to target Werner helicase in tumors with MSI-H or dMMR. This development program reflects Bayer’s focus on precision oncology and on therapies for patients with advanced colorectal cancer who have limited treatment options.
Where the stock trades today
The Bayer shares (DE000BAY0017) trade on Xetra at 38.58 euros as of 2026-06-23, 18:09, according to German exchange data.
Key data on the Bayer shares
- Company: Bayer Aktiengesellschaft
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of 2026-06-23, 18:09): 38.58 EUR
- Market cap: 38.6 billion EUR (as of 2026-06-23)
- Sector / industry: Pharmaceuticals, Biotechnology & Life Sciences
- Index membership: DAX, STOXX Europe 600
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Investors should conduct their own research and, where appropriate, consult a qualified financial adviser.
